RASopathies

A phase II basket trial demonstrates that vosoritide significantly increases growth velocity in children with RASopathies, ACAN, and NPR2 deficiencies, with an acceptable short-term safety profile, suggesting its potential as a precision therapy targeting MAPK pathway growth disorders.